Clinical Trial Update: Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets [Phase 1]

View source ↗

Summary

Phase 1 study comparing the relative bioavailability of two new fixed-dose combination tablets containing dolutegravir, abacavir, and lamivudine in healthy subj…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• dolutegravir/abacavir/lamivudine fixed-dose combination tablet (Formulation A) (dolutegravir/abacavir/lamivudine)
• dolutegravir/abacavir/lamivudine fixed-dose combination tablet (Formulation B) (dolutegravir/abacavir/lamivudine)

Snippet

Sponsor: ViiV Healthcare | Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED